03/01/2018 21:05:00

Zai Lab Limited to present at the 36th Annual J.P. Morgan Healthcare Conference

SHANGHAI, China, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that Chief Executive Officer, Samantha Du, will present at the 36th Annual J.P. Morgan Healthcare Conference. 

Details of the presentation are as follows:

The 36th Annual J.P. Morgan Healthcare Conference

Date: Wednesday, January 10, 2018

Location: San Francisco, CA, USA

Presentation Time: 10:00 AM PT

Individuals may access a live webcast of the conference presentation on the Zai Lab website at www.zailaboratory.com under "Events & Presentations" in the "Investors" section.  A replay of the webcast will be available on this site for 90 days following the live event.

About Zai Lab

Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.

Contact:

Zai Lab

Jonathan Wang

+86 21 6163 2588

jwang@zailaboratory.com

The Trout Group

John Graziano

+1 646 378 2942

jgraziano@troutgroup.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
22 Jun
I:SP500
  Hejsa alle sammen   Konjunktur: Ifølge vedlagte teoretiske model omkring de ledende indikatorer be..
48
20 Jun
GEN
Et gammelt indlæg:   Hvis man kigger lidt tilbage i tiden og ser på de kvartalsvise resultater, så l..
36
18 Jun
PNDORA
              Jeg har lavet en fuld analyse på Pandora, som er en blanding af en regnskabs-analyse o..
17
20 Jun
GEN
Hold da kæft, du er godt nok en sur (gammel ?) mand......
16
19 Jun
VWS
https://www.vestas.com/en/media/company-news?n=1763161#!NewsView
12
19 Jun
I:SP500
Trump har bedt det amerikanske handelsministerie om en liste over kinesiske varer for 200 mia USD, s..
12
18 Jun
BAVA
Dvs de bør være der indenfor 9 børsdage... Hvis disse data gentager det som er kommet frem indtil nu..
12
23 Jun
 
USA blev løftet ud af recession under Obama. Punktum. Økonomien kørte fint da Trump blev valgt og er..
11
20 Jun
NOVO-B
Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenl..
11
18 Jun
VWS
I begyndelse af året havde grædekonerne kronede dage, hvad angår ordreindtag. Det har li'som ændret ..
11

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
2
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
3
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
4
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
5
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2018 06:09:17
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-24 07:09:17 - 2018-06-24 06:09:17 - 1000 - Website: OKAY